621
Views
4
CrossRef citations to date
0
Altmetric
Letter

Erosive Conjunctival and Corneal Inflammatory Changes in a Patient Receiving Weekly Docetaxel for Breast Cancer

, MD, , MD, , MD, , MD & , MD
Pages 164-166 | Received 01 Nov 2012, Accepted 03 Jun 2013, Published online: 22 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ghyath Kafa, Mania Horani, Fayyaz Musa, Ahmad Al-Husban, Mohamed Hegab & Noor Asir. (2023) Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab & Docetaxel. Ocular Immunology and Inflammation 31:2, pages 431-436.
Read now

Articles from other publishers (3)

Minas Sakellakis, Nikolaos Spathas, Konstantinos T Tsaousis, Emmanouil N Nikitiadis, Helena Linardou & Vasilios F Diakonis. (2022) Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review. Cureus.
Crossref
Keiichi Aomatsu, Koji Sugioka, Aya Kodama-Takahashi, Masahiko Fukuda, Hiroshi Mishima & Shunji Kusaka. (2020) Corneal Perforation during Combination Chemotherapy including Cetuximab in a Patient with a History of Herpetic Keratitis. Case Reports in Oncological Medicine 2020, pages 1-4.
Crossref
. (2014) Docetaxel. Reactions Weekly 1501:1, pages 19-19.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.